1 week Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,300 shares of the company’s stock, valued at approximately $193,000.
Several other large investors have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Soleno Therapeutics by 208.
1% in the third quarter. Charles Schwab Investment Management Inc. now owns 192,597 shares of the company’s stock valued at $9,724,000 after buying an additional 130,080 shares during the period.
Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Soleno Therapeutics in the third quarter valued at approximately $155,000. State Street Corp increased its position in Soleno Therapeutics by 14.2% during the 3rd quarter.
State Street Corp now owns 1,142,169 shares of the company’s stock valued at $57,668,000 after purchasing an additional 142,033 shares during the period. Wellington Management Group LLP raised its holdings in Soleno Therapeutics by 73.8% during the 3rd quarter.
Wellington Management Group LLP now owns 683,170 shares of the company’s stock worth $34,493,000 after purchasing an additional 290,135 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Soleno Therapeutics by 149.3% in the 3rd quarter.
Barclays PLC now owns 52,545 shares of the company’s stock worth $2,652,000 after purchasing an additional 31,467 shares during the period. 97.42% of the stock is owned by institutional investors.
Insider Buying and Selling at Soleno TherapeuticsIn other Soleno Therapeutics news, CEO Bhatnagar Anish sold 699,095 shares of the business’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total transaction of $47,272,803.
90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12.
The trade was a 54.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Also, VP Michael F. Huang sold 14,583 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.
51, for a total value of $1,013,664.33. Following the completion of the sale, the vice president now directly owns 36,817 shares of the company’s stock, valued at approximately $2,559,149.
67. This trade represents a 28.37 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Over the last three months, insiders have sold 942,672 shares of company stock valued at $64,058,781. Corporate insiders own 12.
30% of the company’s stock. Analyst Ratings ChangesSLNO has been the subject of several recent analyst reports. Stifel Nicolaus increased their price objective on shares of Soleno Therapeutics from $74.
00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, March 28th. Robert W.
Baird lifted their price objective on Soleno Therapeutics from $72.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, March 27th.
UBS Group set a $105.00 target price on Soleno Therapeutics in a research report on Thursday, March 27th. HC Wainwright lifted their target price on Soleno Therapeutics from $70.
00 to $100.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Guggenheim restated a “buy” rating and set a $81.
00 price target (up from $70.00) on shares of Soleno Therapeutics in a report on Friday, March 28th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company.
According to data from MarketBeat, Soleno Therapeutics presently has an average rating of “Buy” and a consensus price target of $99.63.Get Our Latest Report on Soleno TherapeuticsSoleno Therapeutics Stock PerformanceShares of NASDAQ:SLNO opened at $59.
04 on Wednesday. Soleno Therapeutics, Inc. has a 52-week low of $36.
61 and a 52-week high of $74.00. The business’s 50 day simple moving average is $52.
04 and its two-hundred day simple moving average is $50.95. The firm has a market cap of $2.
71 billion, a P/E ratio of -17.78 and a beta of -2.29.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.
86) by ($0.41). On average, equities analysts forecast that Soleno Therapeutics, Inc.
will post -3.72 earnings per share for the current fiscal year. About Soleno Therapeutics (Free Report)Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.Featured StoriesFive stocks we like better than Soleno Therapeutics3 Healthcare Dividend Stocks to BuyTariff-Proof Stocks: 3 Big Bargains With Huge Upside PotentialHow is Compound Interest Calculated?Qualcomm Breaks Down But RSI Signals It’s Severely OversoldWhat Are Earnings Reports?Tesla’s #1 Bull Cuts Target But Says It’s Still a BuyWant to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc.
(NASDAQ:SLNO – Free Report)..
